Current position

The Vanguard Group, Inc.’s Jazz Pharmaceuticals Plc (JAZZ) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

The Vanguard Group, Inc.Verified through Q4 2025
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2014Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares6.05MHighest verified quarter-end share count
Quarters reported6Verified quarters with shares above zero
What happened?

The Vanguard Group, Inc. first reported Jazz Pharmaceuticals Plc in Q3 2014. The reported position was increased and reduced across later filings. The Vanguard Group, Inc. currently reports 5.92M shares. The latest verified filing showed: Bought 0.2% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2025
Bought 0.2% more+10.20K shares · 5.92M shares reported after the change
Filing context

Quarter-end price $170.00

Q4 2022
Bought 2.7% more+161.86K shares · 6.05M shares reported after the change
Filing context

Quarter-end price $159.31

Q3 2021
Sold 0.10% of the position−5.31K shares · 5.48M shares remained
Filing context

Quarter-end price $130.21

Q1 2017
Bought 3.5% more+152.07K shares · 4.52M shares reported after the change
Filing context

Quarter-end price $145.13

Q3 2015
Bought 2.2% more+85.07K shares · 3.96M shares reported after the change
Filing context

Quarter-end price $132.81

Q3 2014
Bought 5.5% more+169.49K shares · 3.27M shares reported after the change
Filing context

Quarter-end price $160.56

Portfolio importance

How important is Jazz Pharmaceuticals Plc in The Vanguard Group, Inc.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q4 2025
Current rank#717of 4329 reported positions
Peak portfolio weight0.0%Q3 2014
Best historical rank#497Q3 2014
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$243.592026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$170.00Q4 2025

Derived from validated reported value and shares where supported.

Latest verified investor filingQ4 2025 · filed 2026-01-29
Open SEC filing ↗

Coverage is bounded to Vanguard’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Vanguard’s complete global assets, fund-by-fund ownership, exact trade dates or execution prices.